Followers | 36 |
Posts | 2,689 |
Boards Moderated | 0 |
Alias Born | 06/09/2011 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Very interesting and appreciate you sharing this information.
Well said iwasadiver!
Ben Hodges wife Laurie was in this trial with Stage 4 cancer and multiple lesions and tumors as well as failed 2-3 prior treatment regimines and was told her only option was hospice prior to entering the Direct trial. She lived about 20 months from start of treatment and unfortunately passed in December 2015. I think she stopped treatment early when AF started to trash NWBO.
I believe due to DCvax it extended her life that she could spend that time with her husband Ben and very young children. If you go back and look at Ben's posts he was very supportive of DCVax.
I would think in the near future there will be a big PR highlighting these major combo trials (3 sets of companies participating) for DCVax, funding sources, international clinic participation, etc.
There are so many near term potential catalysts due could really impact this stock in the next month or two, most importantly the regulators response to information submitted by NWBO.
Well said!!
Very interesting and thanks for the reply, much appreciated!
montanus, can you explain what this means to ILNS as you obviously placed this post for a reason. Thanks in advance.
Thank you for the quick reply.
Drilla, does this mean if you have 10k shares of HRTPY(GDS) you will now have 5k after the RS? Look forward to your reply! TIA!
Great find and thank you for sharing this article on DCVax, UCLA and Adaptive Biotechnologies.
UCLA Neuro-Oncology with Dr. Liau and Dr. Prins and team have to be Top 5 hospitals in the world in this field. They are working tirelessly on finding a cure for GBM and brain cancers.
Current update on Nasdaq for Institutional Holdings: Great to see Neil Woodford Investment Managment has not sold even (1) share during this regulatory review period.
Owner Name Date Shared Held Change (Shares) Change (%) Value (in 1,000s)
WOODFORD INVESTMENT MANAGEMENT LLP 03/31/2016 25,915,937 0 0.00 40,688
CREDIT SUISSE AG/ 12/31/2015 1,983,682 (791,559) (28.52) 3,114
VANGUARD GROUP INC 12/31/2015 1,817,613 151,206 9.07 2,854
BLACKROCK FUND ADVISORS 12/31/2015 1,294,831 67,024 5.46 2,033
BLACKROCK INSTITUTIONAL TRUST COMPANY, N.A. 12/31/2015 1,149,827 19,620 1.74 1,805
SABBY MANAGEMENT, LLC 12/31/2015 917,942 345,424 60.33 1,441
STATE STREET CORP 12/31/2015 692,484 (1,523) (0.22) 1,087
GOLDMAN SACHS GROUP INC 12/31/2015 622,971 5,045 .82 978
NORTHERN TRUST CORP 12/31/2015 504,000 (9,152) (1.78) 791
MORGAN STANLEY 12/31/2015 355,763 125,694 54.63 559
GEODE CAPITAL MANAGEMENT, LLC 12/31/2015 298,336 533 .18 468
BANK OF NEW YORK MELLON CORP 12/31/2015 244,372 17,983 7.94 384
SUSQUEHANNA INTERNATIONAL GROUP, LLP 12/31/2015 226,986 (534,714) (70.2) 356
OXFORD ASSET MANAGEMENT 12/31/2015 203,147 203,147 New 319
LPL FINANCIAL LLC 12/31/2015 200,658 99,329 98.03 315
<< First< Previous123456Next >Last >>
Institutional Holdings information for this company is filed by major institutions on form 13-F with the Securities and Exchange Commission.
info Learn more about Institutional Holdings
Read more: http://www.nasdaq.com/symbol/nwbo/institutional-holdings#ixzz46vRmZJpl
100k shares have traded since 2:24pm and PPS has not moved below or above $1.67-$1.68......quite strange
The trading volume picked up today in the last 90 minutes...bought another block of shares today, just too enticing at this level. GLTA!
Jessica's blogs have made it on this board before but she is such a remarkable young woman and brain cancer survivor. She adores Dr. Liau as well and considers her one the best in the world as a neuro surgeon. I have been reading her blogs for a few years and she is such a wonderful person who is beating the odds in the fight against brain cancer.
The link below is just one of her blogs which also notes her tumor is banked/frozen at UCLA for DCVax if needed in the future. Great story!
Very well said!
Living Well, Autumn 2016 This article—published in Australia—explains my brain tumor story, quest to heal, integrative cancer care for the whole person, as well as meaning and purpose through my work.
Nice picture with UCLA's Dr L. Liau at bottom on article and DCVax
http://jeanninewalston.com/wp-content/uploads/My-Brain-Tumour-Led-to-My-Purpose.pdf
http://jeanninewalston.com/blog/my-10-recent-articles-you-may-have-missed/
I agree with you 100%! Well said!
Thanks for sharing! Much appreciated!
2.1M shares of NWBO traded with about 200k in last 8 minutes and price moving pennies....mmmmmmm?
From Nasdaq trading on NWBO in last 2 minutes gives nice snapshot of trading last few minutes
14:40:33 $ 1.796 135
14:39:49 $ 1.79 15,000
14:39:45 $ 1.79 10,000
14:39:31 $ 1.80 5,000
14:39:30 $ 1.80 3,400
14:39:30 $ 1.79 100
14:39:30 $ 1.79 100
14:39:30 $ 1.79 200
14:39:30 $ 1.79 100
14:38:55 $ 1.79 200
14:38:53 $ 1.795 100
14:38:37 $ 1.795 100
14:38:37 $ 1.795 200
14:38:37 $ 1.79 100
14:38:37 $ 1.79 5,500
14:38:32 $ 1.7999 3,200
14:38:32 $ 1.7999 2,800
14:38:08 $ 1.79 1,900
Going to close with over 2M shares traded and they are trying hard to keep this below $1.70!
Yes, the science will eventually prove itself out. Great news for GBM patients and you have to love UCLA neuro-oncology team, world class group! The long road to the finish line is near IMO and PPS will take care of itself if regulators approve for treatment of all operable and inoperable solid tumors. GBM International Phase III trial will be the springboard to label extensions down the road. GLTA!
Nice volume today on NWBO up 13% and HOD of $1.84 and markets are in RED!
Great find and post Flip!!Loved Dr. Prins from UCLA's recent presentation
montanus, after reading this report, I agree with you that OX1 worked. Hopefully, we hear something from Dr. Rohn or Mr. Maza!
Austin, I do not disagree with you on the company acting more like a public company and holding quarterly conference calls. This is a concern of mine as well but believe in the science and expect positive regulatory response when issued.
We should find out pretty soon, this month IMO!
Darren's The Anna Horrell Brainwave 100 mile Cycle
I am cycling 100 miles for Brainstrust because Anna needs life saving treatment (link at bottom of post)
Event: The Anna Horrell Brainwave 100 mile Cycle on 16/04/2016
Cognate is the lead manufacturer of DCVax and NWBO may not be their only customer , but most likely their largest by a landslide. It also appears to me a significant portion of the Woodford investment of funds were focused on Sawston UK transactions, buildings improvements/modifications, permitting. NWBO will also pay for their automation manufacturing improvements via equipment with Cognate facilities in Memphis as well as equipment purchased for Sawston.
We can agree to disagree I guess.
Reading the details mimics their preparing for commercialization to me!
Interesting he is reallocating some money in his funds to purchase more shares in small cap biotechs as he stated recently in his blog a couple of weeks ago.
Northwest Biotherapeutics Inc (NWBO) : Woodford Investment Management Llp scooped up 5,454,545 additional shares in Northwest Biotherapeutics Inc during the Q4 period, according to a recent disclosure to the SEC. The investment management firm now holds a total of 25,915,937 shares of Northwest Biotherapeutics Inc which is valued at $36.3 Million.Northwest Biotherapeutics Inc makes up approximately 1.93% of Woodford Investment Management Llp’s portfolio.
By Rich Holloway - March 31, 2016
http://www.streetedition.net/woodford-investment-management-llp-buys-36-3-million-stake-in-northwest-biotherapeutics-inc-nwbo/6461636/
Other Hedge Funds, Including , Blackrock Institutional Trust Company N.a. boosted its stake in NWBO during the Q4 period, The investment management firm added 19,620 additional shares and now holds a total of 1,149,827 shares of Northwest Biotherapeutics Inc which is valued at $1.6 Million.Renaissance Technologies boosted its stake in NWBO during the Q4 period, The investment management firm added 111,275 additional shares and now holds a total of 139,000 shares of Northwest Biotherapeutics Inc which is valued at $194,600.Blackrock Investment Management boosted its stake in NWBO during the Q4 period, The investment management firm added 1,778 additional shares and now holds a total of 165,964 shares of Northwest Biotherapeutics Inc which is valued at $232,350.
Northwest Biotherapeutics Inc closed down -0.1 points or -6.49% at $1.44 with 395,586 shares getting traded on Wednesday. Post opening the session at $1.54, the shares hit an intraday low of $1.4 and an intraday high of $1.55 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
Northwest Biotherapeutics Inc. is a biotechnology company. The Company is focused on developing immunotherapy products to treat cancer. The Company’s platform technology DCVax uses activated dendritic cells to mobilize a patient’s own immune system including T cells B cells and antibodies and natural killer cells among others to attack cancer cells. DCVax is designed to target a set of biomarkers on the patient’s tumor. DCVax product lines are made from the patient’s own dendritic cells which are freshly isolated and matured and activated. The Company’s DCVax product lines include DCVax-L DCVax-Direct and DCVax-Prostate. DCVax-L is made with cancer antigens from tumor lysate. DCVax-Direct incorporates a set of tumor antigens in situ. DCVax-Prostate product line is developed based on the antigen PSMA (Prostate Specific Membrane Antigen) which is found on all late stage prostate cancers.
I am in total agreement with you and it seems the ball is rolling that way now. This little company with amazing patent portfolio is so under the radar as well!
ABM....hopefully Mr. Maza has this already well planned with Shire Friedreich's Ataxia trail data being published and possible Orphan Drug Designation for FA plus royalty payment and/or acquisition of ILNS.
Yes...you have said the Conjumab platform was worth big dollars for a few years. I wish Elliot would provide a nice update to bring the awareness to the potential of this tiny company with the Shire and Pfizer trials now complete and awaiting data being published which could happen any day if they are moving forward with next phase.
I agree and would love to get shareholder update from Elliott and this is a positive move and looks to be lining this up well. Questions is a partnership and outright deal with a big Pharma?
Intellect Neurosciences, Inc. Engages Benjamin D. Freilich, MD, FACS as Senior Medical Affairs Advisor for CONJUMAB-A Antibody Drug Conjugate Program
MARKET WIRE 10:29 AM ET 3/30/2016
ILNS 0.0974up 0 (0%)
QUOTES AS OF 12:23:26 PM ET 03/29/2016
NEW YORK, NY -- (Marketwired) -- 03/30/16 -- Intellect Neurosciences, Inc.(ILNS), a research-based biotechnology company focused on the discovery, development and licensing of novel disease-modifying therapeutics for the treatment and prevention of rare neurodegenerative orphan diseases with no approved therapies, announced today that it has appointed Benjamin D. Freilich, MD, FACS as Senior Medical Affairs Advisor. Dr. Freilich has agreed to assist the company in shaping and guiding the company's CONJUMAB-A antibody drug conjugate (ADC) program, and in particular, to advise the company on the design of CONJUMAB-A and future pre-clinical and clinical studies targeting Age-Related Macular Degeneration (AMD).
Dr. Freilich is certified by the American Board of Ophthalmology and is a retina specialist practicing in New Jersey with a focus on AMD. Dr. Freilich received a BA in biology with Honors from the University of Chicago. He earned his MD degree Summa Cum Laude at the State University of New York Downstate Medical Center, and did his ophthalmology residency at the Mount Sinai School of Medicine. Dr. Freilich completed a two year vitreo-retinal fellowship at the Massachusetts Eye and Ear Infirmary as well as a research fellowship at The Schepens Eye Research Institute, both of Harvard Medical School. Dr. Freilich also attended the Naval Aerospace Medicine Institute where he was certified as a US Navy Flight Surgeon. He served as a Commander in the United States Navy Reserve. Prior to entering private practice, Dr. Freilich was full time academic faculty at SUNY Downstate, and then joined the academic faculty at The Mount Sinai School of Medicine, where he continues to hold the title of Assistant Clinical Professor of Ophthalmology.
The primary focus of Dr. Freilich's private medical practice is the treatment of both atrophic and neovascular Age-Related Macular Degeneration, the dry and wet forms, respectively, of AMD. Dr. Freilich has treated several thousand patients with AMD over the course of his career and is an expert in the latest cutting edge treatments.
Elliot Maza, Chief Executive Officer, CFO and Chairman of Intellect, commented, "We are especially privileged to add Dr. Freilich to our advisory team. Dr. Freilich's experience as a prominent physician treating countless AMD patients will contribute a unique and practical perspective to our CONJUMAB research program in particular, and to all of our research programs more generally. Our lead scientific advisor, Dr. Troy Rohn, Professor, Department of Biological Sciences, Boise State University, and I are excited about working closely with Dr. Freilich to advance CONJUMAB-A for the treatment of AMD."
Dr. Freilich commented, "I am extremely excited to join the Intellect team and contribute to the company's efforts to develop a viable treatment option for patients suffering from the atrophic or dry form of AMD, which can lead to severe visual loss in many patients. At this point in time, there is no truly effective therapy for advanced atrophic AMD. Also, Intellect's potential AMD therapy might prove to be effective at preventing the neovascular form of AMD."
About Intellect Neurosciences, Inc.(ILNS)
Intellect Neurosciences, Inc. (ILNS) is a research-based biotechnology company focused on the discovery, development and licensing of novel disease-modifying therapeutics for the treatment and prevention of rare neurodegenerative, "orphan," diseases with no approved therapies. Our compounds under development include OX1, a high affinity, copper binding molecule that protects the body against free radicals. OX1 (renamed "SHP622") is licensed to Shire plc, which recently completed a single ascending dose and multiple ascending dose Phase 1b clinical study in 55 patients with Friedreich's Ataxia designed to evaluate the safety, tolerability, and PK/PD of SHP622. Details of the study, entitled, "A Phase 1, Randomized, Double-blind, Placebo-controlled, Multicenter, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral VP 20629 in Adult Subjects with Friedreich's Ataxia," may be found at: www.clinicaltrials.gov, identifier NCT01898884. For more information, please visit www.intellectns.com.
Safe Harbor Statements Regarding Forward-Looking Statements
The statements in this letter made by representatives of Intellect Neurosciences(ILNS) relating to matters that are not historical facts, including without limitation, those regarding future performance or financial results, the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Intellect's product candidates and the sufficiency of Intellect's cash and other capital resources, the continued development by Shire of SHP622 or its determination to seek Orphan Drug designation for the pharmaceutical product of SHP622 are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that actual performance or results could materially differ, that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, or Intellect's ability to fund such efforts with or without partners. Intellect undertakes no obligation to update any of these statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as to the date hereof. Accordingly, any forward-looking statements should be read in conjunction with the additional risks and uncertainties detailed in Intellect's filings with the Securities and Exchange Commission, including those discussed in Intellect's Annual Report on Form 10-K for the fiscal year ended June 30, 2015 filed on October 14, 2015 and Quarterly Reports on Form 10-Q for the periods ended September 30, 2015 and December 31, 2015, filed on November 12, 2015 and February 12, 2016, respectively.
For further information contact:
David Zazoff
MDM Worldwide Solutions, Inc.
264 W 40th St, #602
New York, NY 10018
(212) 643-0417
Source: Intellect Neurosciences, Inc.(ILNS)
Looks to be a good move as the PPS is moving up nicely and someone trying to keep this down watching trading the past 3-4 days. All we need is some decent buying volume and this moves up quickly with little resistance.
HRTPY trading up again today...would like to see some buying volume kick in and this could move much higher quickly
123tom, thanks for sharing as I am interested in this move as well. I have been in HRTPY since 2010 as well. Appreciate your posts!
Great points Drilla as very undervalued and expect this PPS to climb higher!
Thanks Drilla! Like the movement on PPS today for HRTPY along with the volume finally moving upward quickly!